<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04120623</url>
  </required_header>
  <id_info>
    <org_study_id>KY20190926-03</org_study_id>
    <nct_id>NCT04120623</nct_id>
  </id_info>
  <brief_title>Therapeutic Effect of Dapagliflozin Combined With CSII on Newly Diagnosed Type 2 Diabetes Mellitus</brief_title>
  <official_title>Therapeutic Effect of Dapagliflozin Combined With CSII on Newly Diagnosed Type 2 Diabetes Mellitus With Continuous Glucose Monitoring System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanjing First Hospital, Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanjing First Hospital, Nanjing Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the effect of dapagliflozin combined with CSII and CSII alone on glucose profile
      in newly diagnosed type 2 diabetes mellitus by continuous glucose monitoring system.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To compare the effect of dapagliflozin combined with continuous subcutaneous insulin infusion
      (CSII) and CSII alone on glucose profile in newly diagnosed type 2 diabetes mellitus by
      continuous glucose monitoring system.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2019</start_date>
  <completion_date type="Anticipated">February 28, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the effect of dapagliflozin combined with CSII on glucose profile</measure>
    <time_frame>5 weeks</time_frame>
    <description>To compare the effect of dapagliflozin combined with CSII and CSII alone on glucose profile(the mean amplitude of glycemic excursions(MAGE),The 24-hrs mean glucose(MG) ) in newly diagnosed type 2 diabetes mellitus by continuous glucose monitoring system</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>the effects of dapagliflozin combined with CSII on weight</measure>
    <time_frame>5 weeks</time_frame>
    <description>To compare the effect of dapagliflozin combined with CSII and CSII alone on weight in kilogram</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the effects of dapagliflozin combined with CSII on blood pressure</measure>
    <time_frame>5 weeks</time_frame>
    <description>To compare the effect of dapagliflozin combined with CSII and CSII alone on blood pressure in mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the effects of dapagliflozin combined with CSII on lipid metabolism(total cholesterol in mmol/l, total glyceride in mmol/l)</measure>
    <time_frame>5 weeks</time_frame>
    <description>To compare the effect of dapagliflozin combined with CSII and CSII alone on lipid metabolism(total cholesterol in mmol/l, total glyceride in mmol/l)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Dapagliflozin combined with CSII</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dapagliflozin 10MG combined with Aspart infused by CSII as glucose lowering therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CSII alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Aspart infused by CSII alone as glucose lowering therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin 10 MG</intervention_name>
    <description>Dapagliflozin 10 MG combined with Insulin Aspart infused by continuous subcutaneous insulin infusion ( CSII).</description>
    <arm_group_label>Dapagliflozin combined with CSII</arm_group_label>
    <other_name>Dapagliflozin combined with CSII</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Aspart</intervention_name>
    <description>Insulin Aspart is infused through continuous subcutaneous insulin infusion ( CSII)</description>
    <arm_group_label>CSII alone</arm_group_label>
    <other_name>CSII alone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  volunteer to participate and be able to sign informed consent prior to the trial.

          -  patients with type 2 diabetes or type 1 diabetes, aged 18-80 years old.

          -  No acute complications such as diabetic ketoacidosis, diabetic hyperosmolar syndrome,
             etc.

          -  Subjects are able and willing to monitor peripheral blood sugar and regularity of diet
             and exercise.

        Exclusion Criteria:

          -  Patients with insulin allergy.

          -  Impaired liver and kidney function with ALT 2.5 times higher than the upper limit of
             normal value; Serum creatinine was 1.3 times higher than the upper limit of normal.

          -  Drug abuse and alcohol dependence in the past 5 years.

          -  Systemic hormone therapy was used in the last three months.

          -  Patients with poor compliance and irregular diet and exercise.

          -  Patients with pregnancy, lactation or pregnancy intention.

          -  Any other obvious conditions or associated diseases determined by the researcher: such
             as severe cardiopulmonary diseases, endocrine diseases, neurological diseases, tumors
             and other diseases, other pancreatic diseases, history of mental diseases.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jianhua Ma</last_name>
    <role>Study Director</role>
    <affiliation>Nanjing First Hospital, Affiliated to Nanjing Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jianhua Ma, Doctor</last_name>
    <phone>8625-52887091</phone>
    <phone_ext>+8618951670116</phone_ext>
    <email>majianhua196503@126.com</email>
  </overall_contact>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 29, 2019</study_first_submitted>
  <study_first_submitted_qc>October 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 9, 2019</study_first_posted>
  <last_update_submitted>October 7, 2019</last_update_submitted>
  <last_update_submitted_qc>October 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Continuous Glucose Monitoring System (CGMS)</keyword>
  <keyword>Dapagliflozin</keyword>
  <keyword>Continuous Subcutaneous Insulin Infusion ( CSII)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Aspart</mesh_term>
    <mesh_term>2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

